CFTR and cystic fibrosis: In our study, at least one patient for each genotype proved to be refractory to essentially all CFTR-modulating therapies tested, despite the fact that our panel included VX-809/VX-770, which are the components of ORKAMBI, the FDA-approved treatment option for CF patients with the ΔF508/ΔF508 genotype.